LAMC3 is one of the most representative genes of a signature that has been validated to be used as an independent prognostic factor for breast cancer in individualized treatment [50], and its low expression has also been related to a worse prognosis in ovarian cancer [51]. This evidence concerns the gene LAMC3 and breast carcinoma.